With new $10.6B fund, Hillhouse Capital sets the stage for splashy Asia-focused biotech deals
Having thrown its weight behind some of the biggest biotech financing rounds of the year, China’s private equity powerhouse Hillhouse Capital has reloaded with a $10.6 billion fund.
Other than healthcare, Hillhouse Fund IV will also pursue opportunities in consumer, technology and services sectors globally, though Asia remains the key focus. It’s one of the largest private equity fundraisings in 2018, according to Bloomberg.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.